The in vitro activity of enrofloxacin against 73 Mycoplasma synoviae field strains isolated in Israel and Europe was determined by broth microdilution. Decreased susceptibility to enrofloxacin was identified in 59% of strains, with the MICs ranging from 1 to >16 g/ml. The estimated MIC 50 and MIC 90 values for enrofloxacin were 2 and 8 g/ml, respectively. Moreover, this study showed that 92% of recent Israeli field isolates (2009 to 2011) of M. synoviae have MICs of >2 g/ml to enrofloxacin. Comparison of the quinolone resistance-determining regions (QRDRs) in M. synoviae isolates revealed a clear correlation between the presence of one of the amino acid substitutions Asp79-Asn, Thr80-Ala/Ile, Ser81-Pro, and Asp84-Asn/Tyr/His of the ParC QRDR and decreased susceptibility to enrofloxacin (MIC, >1 g/ml). Amino acid substitutions at positions GyrA 87, GyrB 401/402, and ParE 420/454 were also identified, but there was no clear-cut correlation with susceptibility to enrofloxacin. Comparison of vlhA molecular profiles revealed the presence of 9 different genotypes in the Israeli M. synoviae field isolates and 10 genotypes in the European isolates; only one vlhA genotype (type 4) was identified in both cohorts. Based on results of vlhA molecular typing, several mechanisms for emergence and dissemination of Israeli enrofloxacin-resistant M. synoviae isolates are suggested.
Mycoplasma synoviae is an economically important pathogen of poultry, causing respiratory disease and infectious synovitis in chickens and turkeys (1). The severity of clinical manifestations of M. synoviae infection ranges from inapparent to severe and is markedly exacerbated by the presence of other bacterial or viral pathogens. In addition, eggshell apex abnormality (EAA) has been recently described as a novel presentation of M. synoviae infection (2, 3).Antibiotic treatment at the beginning of a disease outbreak is sometimes employed to reduce economic losses caused by clinical outbreaks of M. synoviae. Enrofloxacin (En), a broad-spectrum antibiotic related to the class of fluoroquinolones, has been widely used in many countries for treatment of a variety of poultry diseases, mainly those associated with Escherichia coli and Pasteurella multocida but also avian mycoplasmosis (4). However, in some countries the use of En in poultry is not permitted, mainly due to human health concerns; in the United States, En has been banned for use in poultry since 2005.Fluoroquinolones act by inhibition of DNA replication through the formation of a ternary complex with DNA and the active site of DNA replication enzymes (5). Fluoroquinolone resistance occurs primarily through mutations in the quinolone resistance-determining regions (QRDRs) of the parC and/or gyrA gene (encoding the A subunits of DNA gyrase and topoisomerase IV) or the gyrB and/or parE gene (encoding the B subunits of DNA gyrase and topoisomerase IV). Topoisomerase IV (parC gene) has been suggested to be the primary target of En in M. synoviae, based on in vivo selection of strains with decreased ...